The clinical laboratory as a missing stakeholder in Japan’s program medical device (SaMD) framework: regulation, two-step approval, and the analytical-validation bridge

Introduction Japan has built one of the most explicit national pathways for Software as a Medical Device (SaMD), known domestically as program medical devices. Under the DASH for SaMD strategy, a dedicated review office, a single consultation window, two-step (conditional early) approval, real-world-data provisions, and widening reimbursement of digital therapeutics have accelerated market access. Yet the clinical laboratory is almost never named as a stakeholder.Areas covered We examine three structural dependencies of the framework on the clinical laboratory: as the provider of input data whose quality and comparability propagate into SaMD output; as the monitoring partner for reimbursed digital therapeutics carrying laboratory-based eligibility and safety obligations; and as the origin of the analytical- and clinical-validation grammar used to evaluate SaMD. We discuss why these dependencies intensify as SaMD becomes cloud-native, API-first, and adaptive, and the laboratory infrastructure – quality control, external quality assessment, metrological traceability – the SaMD lifecycle underuses. Sources were identified by searching PubMed and Europe PMC through August 2026.Expert opinion The clinical laboratory should be explicitly embedded in Japan’s SaMD framework – in device-qualification decisions, in post-market performance monitoring modeled on external quality assessment, and in standardized laboratory data provision. We close with a five-year outlook.